Joshua Pinto Receives Stock Award at Neumora Therapeutics Inc (NMRA) — SEC Form 4, Aug 21, 2026
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Joshua Pinto CIK 0001992595 |
Director
CEO
|
Joshua Pinto at Neumora Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$21,093
More from this insider at Neumora Therapeutics Inc
| 2026-02-19 | Sell | -$21,093 | View |
| 2026-01-09 | Award | — | View |
| 2025-05-30 | Award | — | View |
| 2025-05-23 | Gift/Other | — | View |
| 2025-02-20 | Sell | -$13,477 | View |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.52 | 2026-08-20 | A - Award/Grant | 500,000 A | $0.00 | 2036-08-20 | 500,000 Common Stock | Direct |
Footnotes (1)
- F1
- 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Show more
Related filings at Neumora Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
113
institutional managers reporting a position
Largest by reported value
- Siren, L.L.C. $14.4M
- Black Rock, Inc. $13.2M
- Softbank Group Corp. $10.4M
5%+ Holders · 13D/G
2 filers
-
Paul L Berns 5.1%
Other insiders at Neumora Therapeutics Inc
GET /v1/forms/4/0001610717-26-000381
API docs
View Original SEC Filing